LEADER 00000nam 2200517 a 4500
001 9781780843278
003 LOFM
006 m eo d
007 cr cn |||m|||a
008 130628s2013 enka ob 001 0 eng d
020 |z9781780843292|q(print)
020 9781780843285|q(ePub)
020 9781780843278|q(eISBN)
024 7 10.2217/9781780843278|2doi
035 (OCoLC)0851776810
035 (CaBNVSL)thg00908300
040 CaBNVSL|cCaBNVSL|dCaBNVSL
050 4 RC271.R26|bM663 2013eb
082 04 616.99/40642|222
245 00 Monoclonal antibodies targeting EGFR/HER2 and clinical
outcomes in cancer treatment|h[electronic resource] /
|ceditor, Jan B. Vermorken.
260 London, England :|bFuture Medicine Ltd (Unitec House, 2
Albert Place, London N3 1QB, UK),|cc2013.
300 1 electronic text (107 p.) :|bcol. ill., digital file.
490 1 The Future Science Group eBook collection,
505 0 Monoclonal antibodies targeting EGFR/HER2 and clinical
outcomes in cancer treatment / Jan B. Vermorken --
Colorectal cancer / Christian Rolfo, Giuseppe Bronte,
Antonio Russo & Marc Peeters -- Breast cancer / Sevilay
Altintas -- Lung cancer and genitourinary cancers / Dirk
Schrijvers -- Tumors of the skin, the CNS and the head and
neck / Pol Specenier -- Gynecologic cancers / Jan B.
Vermorken -- Index.
650 0 Cancer|xChemotherapy.
650 0 Epidermal growth factor.
650 0 HER-2 protein.
650 0 HER-2 gene.
650 0 Monoclonal antibodies|xTherapeutic use.
700 1 Vermorken, Jan B.
710 2 Future Medicine Ltd.
830 0 Future Science Group eBook collection,|x2047-332X.
856 40 |3Future Medicine Ltd.|uhttp://www.futuremedicine.com/doi/
pdf/10.2217/9781780843278
